Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01170663 · ClinicalTrials.gov registry record · Phase 3
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
A Phase 3 study of Gastric Cancer, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 665
- Enrollment target
- 20
- Study locations
NCT01170663: Completed Phase 3 study of Gastric Cancer, sponsored by Eli Lilly and Company.
NCT01170663 is a Phase 3 study of Gastric Cancer that has completed, run by Eli Lilly and Company. The registered enrollment target is 665 participants, above the 315-participant average among 153 other Gastric Cancer trials with a reported enrollment target (111% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01170663, a Phase 3 study of Gastric Cancer, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 665 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.
Primary Outcome
OS time was measured from date of randomization to date of death from any cause. Participants who were not known to have died on or before the date of data cut-off, OS data was censored on the last date (on or before the cut-off date) the participant was known to be alive.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Paclitaxel
- BIOLOGICAL Ramucirumab (IMC-1211B) DP
Study Locations (20)
Other
- ImClone Investigational Site - Buenos Aires
- ImClone Investigational Site - Caba
- ImClone Investigational Site - Rosario
- ImClone Investigational Site - Santa Fe
California
- ImClone Investigational Site - Burbank
- ImClone Investigational Site - Los Angeles
- ImClone Investigational Site - San Francisco
New South Wales
- ImClone Investigational Site - Bankstown
- ImClone Investigational Site - Kogarah
- ImClone Investigational Site - Liverpool
Florida
- ImClone Investigational Site - Jacksonville
- ImClone Investigational Site - Miramar
Georgia
- ImClone Investigational Site - Atlanta
Hawaii
- ImClone Investigational Site - Honolulu
New Jersey
- ImClone Investigational Site - East Orange
New Mexico
- ImClone Investigational Site - Albuquerque
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 665 participants |
| Start Date | 2010-12 |
| Est. Completion | 2017-02 |
| Phase | Phase 3 |
What the finished NCT01170663 record still lists
NCT01170663 is an interventional study that assigns participants to a tested intervention. The registered 665 participants enrollment target is mid-sized for trials with a published cap, above the 315-participant average among 153 other Gastric Cancer trials with a reported enrollment target (111% higher).
The record links to 1 condition, with Gastric Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01170663 names 20 study sites across 12 states, led by Other, California, New South Wales.
Frequently Asked Questions
What is clinical trial NCT01170663 about?
NCT01170663 is a clinical study titled "A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma". This is a Phase III randomized multicenter double-blind, placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab (IMC-1211B) drug product (DP) compared to paclitaxel plus placebo.
What is the current status of trial NCT01170663?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 665 participants. The study started on 2010-12. Estimated completion is 2017-02.
What conditions does trial NCT01170663 study?
This clinical trial studies the following conditions: Gastric Cancer.
What interventions are being tested in trial NCT01170663?
The interventions under investigation include: Placebo (DRUG), Paclitaxel (DRUG), Ramucirumab (IMC-1211B) DP (BIOLOGICAL).
Who is sponsoring clinical trial NCT01170663?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01170663 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Hawaii, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01170663's enrollment target sits among peer trials
665 14th of 153 higher than 140 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
RECRUITING · Phase 3
-
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
RECRUITING · Phase 3
-
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
RECRUITING · Phase 3
-
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
RECRUITING · Phase 3
-
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
ACTIVE NOT RECRUITING · Phase 3
-
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
- NCT06981078 · 666 participants · Phase 2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia